BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 32661214)

  • 1. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
    Saxena A
    J Biosci; 2020; 45(1):. PubMed ID: 32661214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of lethal human coronaviruses.
    Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
    Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy and treatments during COVID-19 era.
    Akula SM; Abrams SL; Steelman LS; Candido S; Libra M; Lerpiriyapong K; Cocco L; Ramazzotti G; Ratti S; Follo MY; Martelli AM; Blalock WL; Piazzi M; Montalto G; Cervello M; Notarbartolo M; Basecke J; McCubrey JA
    Adv Biol Regul; 2020 Aug; 77():100739. PubMed ID: 32773105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
    Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
    Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
    Li H; Liu Z; Ge J
    J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
    Gupta SP
    Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
    Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
    Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19: Immunology and treatment options.
    Felsenstein S; Herbert JA; McNamara PS; Hedrich CM
    Clin Immunol; 2020 Jun; 215():108448. PubMed ID: 32353634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
    Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
    J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic.
    Brufsky A
    J Med Virol; 2020 Jul; 92(7):770-775. PubMed ID: 32293710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel coronavirus SARS-CoV-2 (Covid-19) dynamics inside the human body.
    Saha A; Saha B
    Rev Med Virol; 2020 Sep; 30(5):e2140. PubMed ID: 32686248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).
    Sarkar B; Ullah MA; Johora FT; Taniya MA; Araf Y
    Immunobiology; 2020 May; 225(3):151955. PubMed ID: 32517882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
    Hosoki K; Chakraborty A; Sur S
    J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
    Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
    J Biosci; 2020; 45(1):. PubMed ID: 33184246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 pathophysiology: A review.
    Yuki K; Fujiogi M; Koutsogiannaki S
    Clin Immunol; 2020 Jun; 215():108427. PubMed ID: 32325252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
    Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
    Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.